Navigation Links
Burrill Merchant Banking Advises Faes Farma on Bilastine Licensing Agreement
Date:1/9/2008

SAN FRANCISCO, Jan. 9 /PRNewswire/ -- Burrill Merchant Banking acted as exclusive financial advisor to Faes Farma (Spain) on its recently-completed commercial partnering of bilastine with the Menarini Group (Italy). Under the terms of the agreement, Faes has licensed bilastine rights in Europe and other regions to Menarini for the treatment of seasonal allergic rhinitis.

Bilastine is a new highly selective H1 antihistamine for once daily oral administration. Allergic rhinitis prevalence in Europe is approximately 23% and many patients are under-diagnosed and under-treated. Bilastine has been assessed in multiple human trials involving 4,000 patients, including two pivotal Phase III trials.

The agreement includes milestone payments and royalties of 10-15% of annual sales in the licensed territories, incorporating the 27 EU member states and 24 additional countries in Eastern Europe, Scandinavia, Central Asia and the Mediterranean region. The Menarini Group is a privately held company headquartered in Florence Italy with 12,000 employees and estimated 2007 turnover of euro 2,500M.

About Burrill Merchant Banking

Burrill Merchant Banking assists life science companies to identify, negotiate and close strategic transactions. Service lines include:

-- Mergers & Acquisitions

-- Strategic Partnering from preclinical research to product development

and commercialization

-- Spin-Outs and Divestitures

-- Financing (Private Placements)

-- Advisory Services to define the role of transactions in achieving

strategic objectives

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Private Equity, Venture Capital, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. The company's 60 person scientific and business team, supported by its 40-person Advisory Boards, the strategic and financial network of its limited partners, and the close relationships developed with numerous life sciences companies and management, provide Burrill with unparalleled access and insight.

Burrill is the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publishes a wide range of bio-intelligence reports including: The Personalized Medicine Report, The Stem Cell Report, and periodic newsletters covering Canada, China, Europe, India, Japan and Partnering/M&A. In association with the California Healthcare Institute, Burrill publishes The Journal of Life Sciences -- a bimonthly magazine. Burrill's flagship publication is its annual "State of the Industry" report, the most recent 21st Edition being Biotech 2007: Life Sciences - A Global Transformation. The 22nd Edition is entitled Biotech 2008: Life Sciences - A 20/20 Vision to 2020, available 1Q '08. These publications provide the latest insight, intelligence and information on the life sciences industry. http://www.burrillandco.com.


'/>"/>
SOURCE Burrill Merchant Banking
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The 3rd Annual Burrill Personalized Medicine Meeting November 12-13, 2007 in San Francisco
2. Burrill & Company Announces Promotions
3. Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
4. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
7. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
8. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
9. Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug
10. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
11. Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 23, 2017  Spherix Incorporated (Nasdaq: SPEX ... fostering of technology and monetization of intellectual property, today ... Anthony Hayes , Chief Executive Officer ... continue to communicate with shareholders about the status of ... diligence on other patent assets that fit with our ...
(Date:1/23/2017)... , Jan. 23, 2017 /PRNewswire/ - Resverlogix Corp. ... results from the New Zealand ... patients. The data showed remarkable results in reducing inflamed ... healthy control patients. It is believed that this is ... connection of this type can be made between epigenetic ...
(Date:1/23/2017)... ... January 23, 2017 , ... Calvert Labs, Inc. ... Safety and Senior Director, Safety Pharmacology. Dr. Thomas earned his M.Sc. and ... Thomas’ career as an academic and industry preclinical drug developer spans more than ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... replacement at the Caribbean Neurosciences Symposium (CANS) annual meeting in Montego Bay, Jamaica ... technology and host a hands-on workshop for surgeons to experience the simplicity of ...
Breaking Biology Technology:
(Date:1/13/2017)... 13, 2017 Sandata Technologies, LLC, a ... homecare industry, including Electronic Visit Verification™ (EVV™), announced ... Jugs, as Senior Vice President of Product Management. ... of homecare experience to Sandata, where he will ... to align Sandata,s suite of solutions with the ...
(Date:1/12/2017)... 12, 2017  New research undertaken by Fit Small ... future.  1,000 participants were simply asked which office technology had ... may consider standard issue.  Insights on what will ... gathered from futurists and industry leaders including Penelope Trunk ... .  Some of these findings ...
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
Breaking Biology News(10 mins):